China News Service, Beijing, June 6 (Reporter Zhang Su) In China, the incidence and mortality of lung cancer are ranked first.
The reporter learned from Xinda Biotechnology on the 6th that the domestic innovative drug PD-1 inhibitor Daboshu has been approved by the National Medical Products Administration to combine chemotherapy in the first-line treatment of advanced squamous non-small cell lung cancer.
Medical experts point out that lung cancer is divided into small cell lung cancer and non-small cell lung cancer according to histological type. Among them, cases of non-small cell lung cancer account for about 80% to 85% of lung cancer patients.
About 30% of Chinese patients with non-small cell lung cancer have squamous non-small cell lung cancer.
Professor Zhou Caicun, director of the oncology department of Shanghai Pulmonary Hospital, said that in the past two decades, the development of non-small cell lung cancer drugs has mainly focused on non-squamous non-small cell lung cancer. Squamous non-small cell lung cancer is due to its unique epidemiology and organization. Pathological and molecular biological characteristics, drug development is relatively slow, and patients lack effective drug treatment.
“Tumor, as the number one disease threatening human life and health, has always been a tough topic for researchers and clinicians. Anti-tumor biologics are also an important research field in our product pipeline.” said Dr. Liu Yongjun, President of Cinda Bio, Dabo Shu has a complete layout in the field of squamous non-small cell lung cancer, providing new drug options for lung squamous cell carcinoma patients who previously lacked effective treatment drugs.
It is reported that in Daboshu's layout for squamous non-small cell lung cancer, in addition to the first-line treatment approved this time, the key phase III clinical study of the second-line treatment also achieved positive results.
The listing application was also accepted by the State Drug Administration in January this year.
According to the R&D team, it is currently working hard to expand the scope of indications for Daboshu and has carried out more than 20 clinical studies on Daboshu worldwide.
Clinical research in the fields of colorectal cancer, gastric cancer, cholangiocarcinoma, cervical cancer, lymphoma, and melanoma is also underway.
It is worth mentioning that Daboshu is the first PD-1 in the country to enter the national medical insurance catalog.
In January of this year, Cinda Biotech responded to the Beijing Kangmeng Foundation's call to provide medical aid to cancer patients who were impoverished by illness, and participated in the "Shuxinkeyi-Tumor Immunotherapy Patient Relief Project" to effectively reduce the financial burden of patients.
(Finish)